PT2303330T - Composições farmacêuticas para o tratamento da doença de parkinson - Google Patents

Composições farmacêuticas para o tratamento da doença de parkinson

Info

Publication number
PT2303330T
PT2303330T PT97580252T PT09758025T PT2303330T PT 2303330 T PT2303330 T PT 2303330T PT 97580252 T PT97580252 T PT 97580252T PT 09758025 T PT09758025 T PT 09758025T PT 2303330 T PT2303330 T PT 2303330T
Authority
PT
Portugal
Prior art keywords
parkinson
disease
treatment
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
PT97580252T
Other languages
English (en)
Inventor
Lamensdorf Itschak
Sela Yoram
Original Assignee
Pharma Two B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2303330(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Two B Ltd filed Critical Pharma Two B Ltd
Publication of PT2303330T publication Critical patent/PT2303330T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT97580252T 2008-06-06 2009-06-07 Composições farmacêuticas para o tratamento da doença de parkinson PT2303330T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5932608P 2008-06-06 2008-06-06

Publications (1)

Publication Number Publication Date
PT2303330T true PT2303330T (pt) 2018-02-12

Family

ID=41051156

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97580252T PT2303330T (pt) 2008-06-06 2009-06-07 Composições farmacêuticas para o tratamento da doença de parkinson

Country Status (22)

Country Link
US (2) US8969417B2 (pt)
EP (1) EP2303330B2 (pt)
JP (1) JP5648216B2 (pt)
KR (1) KR101613749B1 (pt)
CN (1) CN102105169B (pt)
AU (1) AU2009254730B2 (pt)
BR (1) BRPI0914902B8 (pt)
CA (1) CA2726833C (pt)
CL (1) CL2010001358A1 (pt)
CY (1) CY1119865T1 (pt)
DK (1) DK2303330T4 (pt)
ES (1) ES2659394T5 (pt)
HU (1) HUE037974T2 (pt)
LT (1) LT2303330T (pt)
MX (1) MX2010013393A (pt)
NO (1) NO2303330T3 (pt)
NZ (1) NZ590291A (pt)
PL (1) PL2303330T5 (pt)
PT (1) PT2303330T (pt)
RU (1) RU2540470C9 (pt)
WO (1) WO2009147681A1 (pt)
ZA (1) ZA201100034B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2531181T (lt) 2010-02-03 2019-07-10 Pharma Two B Ltd. Rasagilino uždelsto atpalaidavimo kompozicijos ir jų panaudojimas
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
HUE038029T2 (hu) * 2012-01-12 2018-09-28 Pharma Two B Ltd Parkinson-betegség rögzített dózisú kombinációs terápiája
WO2013168032A1 (en) * 2012-05-07 2013-11-14 Micro Labs Limited Pharmaceutical compositions comprising rasagiline
KR101320945B1 (ko) * 2012-07-03 2013-10-23 주식회사파마킹 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
US20150216850A1 (en) * 2012-09-27 2015-08-06 Michael Hayden Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
CA3212170A1 (en) 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
EP2808023A1 (en) * 2013-05-30 2014-12-03 Université Pierre et Marie Curie (Paris 6) New drug for the treatment and/or prevention of depressive disorders
CN104473942A (zh) * 2014-12-12 2015-04-01 青岛大学 一种抗帕金森氏病的药物组合物
WO2016190766A1 (en) 2015-05-26 2016-12-01 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Compositions for use in treating parkinson's disease and related disorders
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
US20190343780A1 (en) * 2016-12-22 2019-11-14 Rvx Therapeutics Ltd. Low dose drug combinations for use in preventing and treating neuronal damage
US11253594B2 (en) * 2017-07-07 2022-02-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Drug combinations for protecting against neuronal cell death
JP6596483B2 (ja) * 2017-12-28 2019-10-23 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物
WO2020084168A1 (en) * 2018-10-26 2020-04-30 Icm (Institut Du Cerveau Et De La Moelle Épinière) Tetracycline compound for treating drug-induced dyskinesia
WO2020227646A1 (en) * 2019-05-09 2020-11-12 Apkarian Technologies Llc Methods and compositions for treating pain
WO2021109880A1 (zh) 2019-12-06 2021-06-10 上海医药集团股份有限公司 药物组合物、成套药盒及其应用
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
TW202227131A (zh) * 2020-09-10 2022-07-16 愛爾蘭商普羅佘納生物科技有限公司 帕金森氏症之治療
CA3194665A1 (en) 2020-10-05 2022-04-14 Jia-Ning Xiang Modified release compositions of a gamma-hydroxybutyric acid derivative
CN114762684B (zh) * 2021-01-14 2023-11-21 华益泰康药业股份有限公司 一种治疗帕金森的缓释胶囊及其制备方法
CN117098533A (zh) 2021-03-19 2023-11-21 凯瑞康宁公司 γ-羟基丁酸衍生物的组合释放型制剂的药物动力学

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2029805T3 (es) * 1986-04-16 1992-10-01 Asta Pharma Aktiengesellschaft Procedimiento para preparar un producto que contiene amantadina y selegilina en asociacion sinergica.
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
ATE258067T1 (de) * 1995-05-26 2004-02-15 Pfizer Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
AU2001255849B8 (en) 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil
WO2005079795A2 (en) 2004-02-20 2005-09-01 Novartis Ag Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
WO2007002518A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
US20090325911A1 (en) 2005-10-21 2009-12-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Androgens for the Treatment of Parkinson's Disease
WO2007073702A2 (es) * 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
HUE028777T2 (en) 2006-02-17 2017-01-30 Ratiopharm Gmbh Deuterated catecholamine derivatives and medicaments containing these compounds
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
CA2652251A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods for using the same
JP5539717B2 (ja) 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
TW200820963A (en) 2006-07-28 2008-05-16 Xenoport Inc Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
EP2069300A2 (en) 2006-08-21 2009-06-17 Prexa Pharmaceuticals, Inc. Multimediator transporter inhibitors for use in treatment of central nervous system disorders
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
MX2009004822A (es) 2006-11-01 2009-10-19 Purdue Pharma Lp Compuestos de fenilpropionamida y usos de los mismos.
EP2150239A1 (en) * 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
ES2659394T3 (es) 2018-03-15
CN102105169A (zh) 2011-06-22
RU2010154716A (ru) 2012-08-10
CN102105169B (zh) 2014-09-10
LT2303330T (lt) 2018-04-10
PL2303330T3 (pl) 2018-04-30
AU2009254730B2 (en) 2014-06-26
EP2303330B1 (en) 2017-11-15
CA2726833C (en) 2016-03-22
CL2010001358A1 (es) 2011-08-19
NZ590291A (en) 2013-11-29
US8969417B2 (en) 2015-03-03
MX2010013393A (es) 2011-06-21
US9259418B2 (en) 2016-02-16
BRPI0914902B8 (pt) 2022-04-12
PL2303330T5 (pl) 2021-10-25
JP5648216B2 (ja) 2015-01-07
AU2009254730A1 (en) 2009-12-10
CY1119865T1 (el) 2018-06-27
CA2726833A1 (en) 2009-12-10
RU2540470C2 (ru) 2015-02-10
ZA201100034B (en) 2012-04-25
DK2303330T4 (da) 2021-09-13
JP2011522035A (ja) 2011-07-28
BRPI0914902B1 (pt) 2022-02-22
RU2540470C9 (ru) 2015-07-20
WO2009147681A1 (en) 2009-12-10
KR101613749B1 (ko) 2016-04-19
US20110230513A1 (en) 2011-09-22
HUE037974T2 (hu) 2018-09-28
DK2303330T3 (en) 2018-02-26
ES2659394T5 (es) 2021-12-13
NO2303330T3 (pt) 2018-04-14
BRPI0914902A2 (pt) 2017-06-20
KR20110031181A (ko) 2011-03-24
EP2303330B2 (en) 2021-06-16
US20150133513A1 (en) 2015-05-14
EP2303330A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
ZA201100034B (en) Pharmaceutical compositions for treatment of parkinson's disease
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2382176A4 (en) USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ZA201002751B (en) Compositions for treating parkinson's disease
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
EP2312945A4 (en) PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
IL230335A (en) A drug used to treat cartilage disease
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
SI2197883T1 (sl) Derivat kateholamina uporaben za zdravljenje parkinsonove bolezni
EP2312946A4 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2268647A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
EP2213303A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
EP2210621A4 (en) COMPOSITION FOR THE TREATMENT OF JOINT DISEASES
ZA201009072B (en) Pharmaceutical composition for the treatment of premature ejaculation
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
IL217149A0 (en) Compositions and methods for treating parkinson's disease
EP2349308A4 (en) COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2413696A4 (en) COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2517698A4 (en) ACTIVE AGENT FOR THE TREATMENT OF MORBUS PARKINSON
EP2517704A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND METHOD OF MAKING SAME
SI2344166T1 (sl) Farmacevtska sestava za zdravljenje gastrointestinalnih iritacij
EP2305629A4 (en) THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE